Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK233705 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary disease.
Epistemonikos ID: eba3a5161fdc8a2ffc22d5b3cf337713045cc62e
First added on: May 04, 2024